Acta gastro-enterologica Belgica · 2003
Long-term albendazole treatment in one case of alveolar echinococcosis. Case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cökmez Atilla, Aydede Hasan, Gür Serhat, Tarcan Ercüment
Аннотация
AIMS: Curative therapy of alveolar echinococcosis is total surgical removal of the infected tissue and concomitant chemotherapy. However, this curative resection can be done on a limited number of patients, for the remaining ones various palliative procedures can be performed.
METHOD: In this article it is aimed to present the result of long-term albendazole treatment in patient who had a palliative hepatojejunostomy for obstructive jaundice due to unresectable alveolar echinococcosis.
RESULTS: Systemic albendazole treatment was initiated in this patient after palliative hepatojejunostomy procedure. During follow up there was no abnormality in blood chemistry and a considerable regression in size of the lesion was found in postoperative month 24. Residual hepatic lesion was histopathologically documented and showed apparently non-viable parasitic cysts by biopsy. These findings suggest the long-term albendazole therapy being parasitocidal.
CONCLUSIONS: Palliative or mass reduction surgery combined with long-term albendazole therapy is the standard therapy for advanced disease, especially when curative resection might result in significant morbidity and mortality.
METHOD: In this article it is aimed to present the result of long-term albendazole treatment in patient who had a palliative hepatojejunostomy for obstructive jaundice due to unresectable alveolar echinococcosis.
RESULTS: Systemic albendazole treatment was initiated in this patient after palliative hepatojejunostomy procedure. During follow up there was no abnormality in blood chemistry and a considerable regression in size of the lesion was found in postoperative month 24. Residual hepatic lesion was histopathologically documented and showed apparently non-viable parasitic cysts by biopsy. These findings suggest the long-term albendazole therapy being parasitocidal.
CONCLUSIONS: Palliative or mass reduction surgery combined with long-term albendazole therapy is the standard therapy for advanced disease, especially when curative resection might result in significant morbidity and mortality.